PDXDC2P

Across TCGA pan-cancer cohorts, PDXDC2P RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of PDXDC2P’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where PDXDC2P RNA is repressed in tumor relative to normal tissue. In most cancer types PDXDC2P is over-expressed in tumor, although a few such as THCA and COAD show the opposite, repressed pattern.

THCA, BRCA, and BLCA are the cancer types where PDXDC2P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PDXDC2P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	II,III,IV	−0.132	<.001	8	view →
BRCA	All	All	+0.107	.004	4	view →
BLCA	All	III,IV	+0.155	.030	3	view →
LIHC	All	All	+0.042	.007	3	view →
COAD	Female	III,IV	−0.122	.014	2	view →
PRAD	All	All	+0.110	.001	2	view →
STAD	All	All	+0.108	.021	2	view →
KIRP	Male	All	−0.076	.010	2	view →
KICH	Female	II,III,IV	−0.095	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

PDXDC2P–THCA

Open the THCA breakdown →